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The gastrointestinal (GI) nematode Strongyloides stercoralis (S.s.) causes human strongyloidiasis, a potentially lifethreatening disease that currently affects over 600 million people globally. The uniquely pernicious aspect of S.s.
infection, as compared to all other GI nematodes, is its autoinfective larval stage (L3a) that maintains a low-grade
chronic infection, allowing undetectable persistence for decades. Infected individuals who are administered
glucocorticoid therapy can develop a rapid and often lethal hyperinfection syndrome within days. Hyperinfection
patients often present with dramatic increases in first- and second-stage larvae and L3a in their GI tract, with L3a
widely disseminating throughout host organs leading to sepsis. How glucocorticoid administration drives
hyperinfection remains a critical unanswered question; specifically, it is unknown whether these steroids pro
mote hyperinfection through eliminating essential host protective mechanisms and/or through dysregulating
parasite development. This current deficiency in understanding is largely due to the previous absence of a
genetically defined mouse model that would support all S.s. life-cycle stages and the lack of successful ap
proaches for S.s. genetic manipulation. However, there are currently new possibilities through the recent
demonstration that immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice support sub-clinical infections
that can be transformed to lethal hyperinfection syndrome following glucocorticoid administration. This is
coupled with advances in transcriptomics, transgenesis, and gene inactivation strategies that now allow rigorous
scientific inquiry into S.s. biology. We propose that combining in vivo manipulation of host immunity and deep
immunoprofiling strategies with the latest advances in S.s. transcriptomics, piggyBac transposon-mediated
transgene insertion, and CRISPR/Cas-9-mediated gene inactivation will facilitate new insights into the mecha
nisms that could be targeted to block lethality in humans with S.s. hyperinfection.

1. Introduction
The human parasitic nematode Strongyloides stercoralis infects over
600 million people worldwide, typically in tropical and developing
countries [1,2], although transmission also occurs in rural parts of
Australia, the United States, and other developed countries [3,4]. People
become infected via direct skin penetration by infective third-stage
larvae (iL3) that are present in fecally-contaminated soil [5] (Fig. 1).
Infections initially may result in a skin rash, cough, dyspnea, diarrhea,
constipation, weight loss, and/or abdominal pain, but then typically

become sub-clinical aside from intermittent abdominal pain [6].
Chronic infections often go undiagnosed because first-stage larvae (L1)
released in feces may be present in variable or low numbers and are also
difficult to identify with commonly used parasitological approaches
such as the fecal float technique [7].
In contrast to other human parasitic nematodes that cannot replicate
inside the host, S. stercoralis typically forms low numbers of auto
infective third-stage larvae (L3a) that permit the parasite to complete its
life cycle within the host and allow infections to persist for decades [5]
(Fig. 1). Strikingly, when people who have maintained a sub-clinical

Abbreviations: CRISPR, clustered regularly interspaced short palindromic repeats; GI, gastrointestinal; HTLV-1, human T-cell lymphotropic virus type 1; IL,
interleukin; ILC2s, type 2 innate lymphoid cells; iL3, infective third-stage larvae; L1, first-stage larvae; L3a, autoinfective third-stage larvae; MPA, methylprednis
olone acetate; NSG, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ.
* Corresponding author.
E-mail addresses: debroski@vet.upenn.edu (D.R. Herbert), jonathan.stoltzfus@millersville.edu (J.D.C. Stoltzfus), hrossi@sas.upenn.edu (H.L. Rossi), david.
abraham@jefferson.edu (D. Abraham).
https://doi.org/10.1016/j.molbiopara.2022.111511
Received 23 March 2022; Received in revised form 1 August 2022; Accepted 18 August 2022
Available online 22 August 2022
0166-6851/© 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).

D.R. Herbert et al.

Molecular & Biochemical Parasitology 251 (2022) 111511

infection for years are administered glucocorticoids (e.g., the prodrug
prednisone, prednisone’s biologically active metabolite prednisolone,
dexamethasone, or methylprednisolone acetate (MPA)), the number of
L3a often rapidly increases, which penetrate through the gut and
migrate through the host, resulting in additional parasitic adults that in
turn produce increasing large numbers of L3a; this uncontrolled increase
in parasite numbers, termed hyperinfection, can quickly overwhelm the
host [8–10] (Fig. 2). Hyperinfection is typically accompanied by
disseminated strongyloidiasis, when larvae extend beyond the normal
migratory route (i.e., skin, lung, and gastrointestinal tract; see Fig. 1)
and enter other vital organs (e.g., brain, kidney, and liver). The out
comes of this increased migration and tissue damage include sepsis,
shock, meningitis, disseminated intravascular coagulation, renal failure,
and/or respiratory failure. In untreated patients, hyperinfection results
in nearly 100% mortality. Mortality rates can still exceed 70% even with
aggressive anthelminthic treatment [11], which is largely due to sepsis
that results from enteric bacteria carried into multiple organs by
migrating larvae [6]. While there are several types of conditions that
may promote hyperinfection, such as human T-cell lymphotropic virus
type 1 (HTLV-1) coinfection, organ transplantation, or Cushing’s disease
[5,12], the overwhelming majority of hyperinfection and disseminated
strongyloidiasis cases are thought to occur following glucocorticoid
administration [6,13]. The recent use of glucocorticoids as common
treatment for COVID-19 patients has made hyperinfection a serious
acute clinical care problem [14]. The anthelminthic drug of choice to
treat uncomplicated S. stercoralis infections is ivermectin. However,
ivermectin has limited efficacy against L3a and its efficacy for pre
venting mortality during hyperinfection varies case by case [6,15].

Surprisingly, the mechanisms by which glucocorticoids cause the rapid
induction of hyperinfection remain entirely unknown.
2. S. stercoralis life cycle: autoinfection as a gateway to
hyperinfection
In the mammalian host, S. stercoralis parasitic females reside in the
crypts of the small intestine where they reproduce by mitotic parthe
nogenesis [16] (Fig. 1E). Eggs laid by the parasitic female in the host
mucosal tissue hatch almost immediately, resulting in post-parasitic L1
in the host small intestine that can be either female or male [5]. In
uncomplicated infections, post-parasitic larvae excreted in the feces are
predominantly rhabditiform (short, tri-lobed pharynx used for feeding)
L1 [17] (Fig. 1A). However, through mechanisms that remain unclear, a
small percentage of female L1 rapidly molt into L2 and further into the
L3a stage by the time the larvae reach the large intestine, which allows
for re-infection of the host prior to elimination in the feces, thereby
maintaining chronic parasitism [18] (Fig. 1F). L3a, which are all female,
typically autoinfect by penetrating the bowel mucosa or the perianal
skin [5] (Fig. 1B, red). L3a may follow a similar migratory route within
the host as iL3 that enter through the skin—i.e., they are flushed into the
lungs by the circulatory system, get lodged in the pulmonary capillaries,
break out into the alveolar airspace, and then migrate up the trachea
where they are thought to be coughed up, and swallowed to enter the
gastrointestinal (GI) tract (Fig. 1C, D). In the small intestine, iL3 molt
into the L4 stage followed by development into adult-stage partheno
genic females [5,16] (Fig. 1E). However, the rapid amplification of
parasite numbers in hyperinfective bursts suggests other migration
Fig. 1. Strongyloides stercoralis life cycle. (A) Fecallycontaminated soil contains non-parasitic free-living male
and female rhabditiform nematodes that reproduce sexu
ally and lay eggs, which invariably develop into filariform
infective third-stage larvae (iL3, gray). (B) These iL3
penetrate the intact skin of a host (human, primates, dog,
Mongolian gerbil, or NSG mouse) to find their way into the
circulation. (C) They transit through the lungs, (D) then are
coughed up and swallowed. (E) In the gastrointestinal tract
they undergo two molts and develop into mature adult
females, which parthenogenically reproduce to produce
eggs in the mucosa, which hatch immediately. Typically,
first-stage larvae (L1, green) are shed in the feces. (F) Some
of the post-parasitic larvae can mature into autoinfective
third-stage larvae (L3a, red) capable of penetrating the
large intestine and host’s skin around the anal tissue,
perpetuating the parasitic stage of the life cycle in the same
host (B-F repeated). L1 shed in the feces can enter the soil
and undergo four additional molts to re-populate the free
living sexually dimorphic stages (and the cycle continues
from A).
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Fig. 2. Possible mechanisms of Strongyloides hyperinfection. Immunosuppression due to glucocorticoid signaling in the host may restrict myeloid, mast cell, and
eosinophil populations that would normally limit parasite burden, contributing to hyperinfection. Glucocorticoids may also alter the ability of key epithelial effector
cells (e.g., tuft and goblet cells) to aid in anti-helminthic actions. (B) Endogenous or exogenous glucocorticoids, or their metabolites, may target receptors or genes
such as the ecdysone pathway that regulate development of the L1 parasite to accelerate maturation of autoinfective third-stage larvae (L3a) inside the body, thereby
favoring aggressive autoinfection leading to hyperinfection. These two possibilities (A & B) are not mutually exclusive.

routes in addition to the traditionally accepted route through the lungs
[19,20]; this non-canonical migratory route to the small intestine may
also occur in uncomplicated infections [19]. L3a are morphologically
distinct from iL3, in that L3a are both larger in diameter and shorter in
length than iL3, and L3a have a single pointed tail whereas iL3 have a
forked tail [21,22] (Fig. 1B). While other frequently studied Strong
yloides species, including S. ratti, S. papillosus, and S. venezuelensis, have
parthenogenic females that produce L1 that are excreted in the feces,
none of these other Strongyloides species are known to undergo autoin
fection. Thus, studies of hyperinfection and disseminated strongyloidi
asis must be undertaken using S. stercoralis.
In host conditions that promote hyperinfection (e.g., glucocorticoid
administration), the proportion of post-parasitic female L1 precociously
developing into L3a relative to L1 exiting the host in the feces dramat
ically increases as does the fecundity of the parasitic female [20]. Fac
tors contributing to the development of L3a are unclear. One hypothesis
is that L3a form as a result of development at an elevated temperature,
where post-parasitic L1 precociously develop into L3 inside of a 37 ◦ C
host. This is supported by the observation that for S. stercoralis strains
biased towards heterogonic development (i.e., towards the single
free-living generation), the female post-parasitic L1 recovered from the
small intestine and incubated outside the host predominantly develop
into filariform iL3 when cultured at 37 ◦ C, but develop into rhabditiform
L3 when cultured at 22 ◦ C [23,24]. However, the cause of this rapid
development or why L1 in the 37 ◦ C GI tract are typically unaffected is
unknown. A possible contributing factor may be that impaired GI
motility due to glucocorticoid therapy permits greater time for larval
development; however, chronic gastrointestinal motility disorders and
constipation have not been associated with hyperinfection. A second
hypothesis is that the number of L3a is intrinsically regulated as a
function of parasite population density inside the host, and that hyper
infection is a result of disruption of this equilibrium [5,18]. This is
supported by the experimental observation that inoculation of hosts
with a large bolus of iL3 also results in hyperinfection [25].

Additionally, in other Strongyloides species, which do not undergo
autoinfection, a strong host immune response results in post-parasitic
female larvae that preferentially develop via the heterogonic route,
while a weak host immune response results in homogonic (i.e., directly
to iL3) development [26,27], suggesting that S. stercoralis post-parasitic
larval development may also be influenced by the interaction between
the host and the parasite.
3. Animal models and general effects of glucocorticoids
Several animal models have been used to study S. stercoralis hyper
infection, which typically infects humans, non-human primates, and
dogs [5]. Prednisone and its derivatives are glucocorticoids routinely
used in the experimental setting to elicit hyperinfection. Dogs typically
control infections after the acute phase, similar to the course of human
disease, but hyperinfection can be triggered by the administration of
prednisolone [28]. Patas monkeys (Erythrocebus patas) can also be
experimentally infected with S. stercoralis and hyperinfection triggered
with prednisone [29]. Rodent models of S. stercoralis infection, where
hyperinfection can be triggered by glucocorticoids, include both the
Mongolian gerbil (Meriones unguiculatus) [21] and the severely immu
nodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse strain [22].
The endogenous hormones of the adrenal system include glucocor
ticoids and mineralocorticoids, which are together termed corticoste
roids. Whereas mineralocorticoids regulate water and electrolyte
balance, glucocorticoids control body homeostasis and immune re
sponses [30]. Importantly, only glucocorticoids have been reported to
be associated with the development of disseminated strongyloidiasis and
hyperinfection, although the reason for this is not clear. Glucocorticoids
are endogenously produced (e.g., cortisol in humans or corticosterone in
rodents) in response to inflammation and glucocorticoid receptors
function as ligand-dependent transcription factors that regulate gene
expression through an array of mechanisms [31]. Synthetic glucocorti
coids include prednisone, prednisolone, dexamethasone, hydrocortisone
3
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(structurally identical to endogenous cortisol), and MPA. These drugs
are widely used in both human and animal medicine to suppress a wide
array of inflammatory disease states [32,33]. In general, these synthetic
glucocorticoids are more potent than endogenous glucocorticoids, such
as cortisol, due to their enhanced pharmacokinetic and pharmacody
namic properties [34]. Like their endogenous counterparts, these drugs
promote immunosuppression through mechanisms that include direct
binding to glucocorticoid response elements in the DNA, either alone, or
in complex with co-receptors or other transcription factors to change
gene expression [32].

generally dampen signaling via cytokine receptors [31,49,50]. Type 2
innate lymphoid cells (ILC2s) generate IL-5, and this can be suppressed
with glucocorticoid treatment in the context of allergic airway inflam
mation or in cultured airway epithelial cell lines [51]. ILC2s are also
important for immunity against other helminth species [52,53]; thus,
suppression of type 2 cytokine production by ILC2s in immune compe
tent model animals may contribute to glucocorticoid-induced
hyperinfection.
While the highly immunodeficient NSG mouse lacks lymphocytes
(innate and adaptive populations), it still possesses several myeloid
lineage subsets that may be sufficiently functional to hold parasite
expansion in check prior to glucocorticoid administration [22]. These
observations also suggest that myeloid cells and/or specialized epithe
lial cell lineages in NSG mice like tuft cells and goblet cells [54] may
contribute to parasite control normally, but these functions are then lost
following glucocorticoid administration. Intestinal epithelial cells
maintain high immune suppressive tone by secretion of IL-10 and TGF-β
[55]. Glucocorticoids up-regulate immunosuppressive cytokines like
IL-10 to further inhibit immune responses [56]. Outside of their effects
on hematopoietic system, glucocorticoids can have direct,
receptor-mediated effects on nonhematopoietic cells like intestinal
epithelia where they dysregulate mucosal barrier function, cytokine
secretion, and other effector functions [57]. Thus, glucocorticoids may
enhance immune-suppressive signals and membrane permeability,
suppressing immune-mediated killing and allowing parasite transit into
the intestinal lumen. In cultured airway epithelial cells, glucocorticoid
treatment reduced IL-13-evoked goblet cell metaplasia [58]. Similarly,
MPA treatment reduces goblet cell hyperplasia in an airway inflamma
tion model [59]. Other glucocorticoids such as dexamethasone inhibit
expression of a mucus-related mucin protein Muc5A in an
airway-derived cell culture system [60]. Although not explicitly tested
in the gastrointestinal tract, it is possible that changes in goblet cell
hyperplasia
or
mucus
production
may
contribute
to
glucocorticoid-induced S. stercoralis hyperinfection. The effects of
glucocorticoid signaling on tuft cell function or expansion has not been
directly studied. Thus, it is possible that intestinal tuft cells and goblet
cells are perhaps important effector cells that restrict adult or larval
development within the GI tract [54]. In fact, the intestinal immune
landscape of the NSG mouse is poorly defined; therefore, there is a clear
need for systematic immunoprofiling studies to be conducted in the
context of S. stercoralis infection that leverage single-cell RNA
sequencing, immunofluorescence microscopy, and multiparameter flow
cytometry along with adoptive transfer strategies to clearly define the
key immune cells and determine whether they are found in the he
matopoietic or non-hematopoietic system.

4. Two potential mechanisms of glucocorticoid-mediated
hyperinfection
Two hypotheses exist as to why glucocorticoid treatment causes
hyperinfection: 1) glucocorticoids suppress key parts of the immune
system that normally keep the parasite “in check” by killing substantial
numbers of larvae produced by parthenogenic females, and/or 2) glu
cocorticoids and/or their metabolites serve as a molecular mimic for
molting hormones like ecdysone, which drive a rapid change in parasite
gene expression and developmental signaling pathways, thereby causing
the adult worms or L1/L2 stages to preferentially develop into L3a
(Fig. 2). These two hypotheses are not mutually exclusive, and it is
certainly plausible that hyperinfection and disseminated strongyloidi
asis are due to a combination of both processes.
5. Glucocorticoid potential suppression of host anti-helminth
immunity
Regarding the protective nature of host immunity against
S. stercoralis, several redundant mechanisms have been identified and
glucocorticoids could alter these (Fig. 2A). Complement factor C3b is
involved in S. stercoralis killing [35]; the glucocorticoid dexamethasone
reduces secretion of C3b by human macrophages [36], suggesting that
glucocorticoids could reduce C3b efficacy during hyperinfection. There
is a significant role for B cell production of immunoglobulins M and G
that license myeloid lineages cells, including eosinophils, macrophages,
and neutrophils, for antibody-dependent cellular cytotoxicity of
S. stercoralis larvae [37,38]. The reported effects of glucocorticoids on
distinct subsets of immune cells are vast and include: inhibiting
lymphocyte activation, promoting lymphocyte apoptosis, and reprog
ramming of macrophages [32]. It is possible some or all of these effects
may counteract anti-parasitic immune mechanisms. Glucocorticoids can
inhibit expression of proteins required for leukocyte recruitment and
trafficking to the infection site, including e-cadherin, integrins, and
chemokines [31]; in the context of hyperinfection, this could limit
trafficking of important effector cells to sites of parasitic infiltration.
Eosinophils, macrophages, and neutrophils kill and trap larval stages of
S. stercoralis, particularly in the context of extracellular trap formation
[39,40]. Glucocorticoids can affect the formation of neutrophil extra
cellular traps in other inflammatory conditions and are generally
inhibitory [41–43], although MPA treatment enhanced neutrophil trap
formation and bacterial clearance in samples from dogs [44]. Thus, it
remains to be determined how glucocorticoids affect the formation of
extracellular traps in the context of S. stercoralis infection. While not
demonstrated for S. stercoralis, mast cells have been shown to serve an
essential role for immunity against the closely related S. ratti [45,46],
the latter of which maintains high parasite fecundity over the course of
an infection when the host is treated with glucocorticoids in contrast to
declining fecundity over the course of an infection in a
non-immunosuppressed host [47,48]. Glucocorticoids also hinder mast
cell histamine release by suppressing Fcε receptor signaling [31]; thus,
mast cells clearance could be inhibited in the context of
glucocorticoid-induced hyperinfection.
The host protective responses are largely driven by the prototypical
type 2 cytokines interleukin (IL)− 4 and IL-5 [38]. Glucocorticoids can

6. Glucocorticoid metabolites as effectors of parasite
development
Alternatively, a second long-standing hypothesis is that hyper
infection results from modification of glucocorticoids into ecdysone-like
agonists that over-activate ecdysteroid-responsive genes in the parasite
[61], which increases the rate of larval development, frequency of L3a,
and/or rate of L3a migration through the host (Fig. 2B). In support of
this second hypothesis, glucocorticoid-driven hyperinfection can be
avoided in both the NSG mouse and Mongolian gerbil models by
administration of the DAF-12 nuclear hormone receptor ligand
Δ7-dafachronic acid, which reduces the number of L3a and host mor
tality [15,22]. Although the mechanisms responsible for hyperinfection
in an immunocompromised host remain ill-defined, the NSG mouse
lacks both innate and adaptive lymphocytes and only develops hyper
infection after glucocorticoid administration, which implies that
perhaps glucocorticoids directly affect parasite biology in addition to
impacting host physiology.
It is possible that glucocorticoids trigger hyperinfection by either upregulating, mimicking, or being modified into steroid hormones that
4
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increase or alter S. stercoralis development (Fig. 2B). It has been pro
posed that glucocorticoids could be modified into ecdysteroids (e.g.,
ecdysone or 20-hydroxyecdysone), which subsequently increase the rate
of larval production and development, thereby driving hyperinfection
[18]. Evidence supporting this hypothesis includes: an increase in the
reproductive output of S. stercoralis parasitic females in gerbils treated
with MPA [21], an increase in the proportion of larvae developing into
L3a in both gerbils and NSG mice treated with MPA [21,22] and, an
increase in the rate of S. stercoralis development, evidenced by the
precocious development of free-living adult males in the large intestine
of gerbils treated with MPA [62]. However, the increased rate of both
larval production and development in MPA-treated animals may also be
an indirect effect of immunosuppressing the host; but if this were strictly
the case, it is unclear how immunosuppression of the host would cause
post-parasitic L1 to precociously develop into L3a.
While many parasitic nematode species have a gene encoding an
ecdysone receptor and can utilize ecdysone signaling to regulate
development and molting [63–67], the Caenorhabditis elegans genome
does not contain a gene encoding an ecdysone receptor [68] nor does
this species appear to produce endogenous ecdysteroids [69], suggesting
ecdysone signaling is not universal in nematodes. Recently, a homolog
of the ecdysone receptor, Ss-ecr-1, was identified in S. stercoralis [62].
Ss-ecr-1 transcripts are up-regulated in free-living females and devel
oping larvae [62], a pattern similar to insects, suggesting that
S. stercoralis utilizes ecdysone signaling to regulate development.
Whether this endogenous signaling can be altered by exogenous ligands
remains unknown in S. stercoralis, although it is likely, given that several
ecdysone receptor agonists and antagonists regulate Brugia malayi
development [70]. Additionally, it is unknown whether the endogenous
ligand of Ss-ECR-1 is ecdysone/20-hydroxyecdysone, one of the other
537 ecdysteroids that have been characterized [71], or some other
undescribed ecdysteroid.
A key piece of this hypothesis is that glucocorticoids must be
metabolized into molecules that can activate the ecdysone receptor in
the parasite. It is unlikely that the glucocorticoids themselves have a
direct effect on the parasite, as they are structurally dissimilar to ecdy
sone [72] and MPA does not inhibit S. stercoralis post-parasitic L1
development into iL3 at 37 ◦ C [22]. It is unknown whether glucocorti
coids can be metabolized into ecdysteroids, either by the host, the
parasite, or the gut microbiome. While many of the metabolites of
prednisolone and MPA have been characterized in humans [73,74], it is
unknown whether any of these can activate the ecdysone receptor. In the
parasite, glucocorticoid metabolism would presumably be carried out by
cytochrome P450 enzymes [75]. Since all 26 cytochrome P450-encoding
genes have been identified in S. stercoralis [24] and can be expressed in
insect cells [15], it should thus be possible to identify any parasite cy
tochrome P450 enzyme(s) potentially involved in this process.
It is also possible that glucocorticoids or their metabolites regulate
S. stercoralis development through processes independent of ecdysone
signaling. The S. stercoralis genome encodes multiple orphan nuclear
hormone receptors [62,76], which likely have various roles in control
ling parasite development—potentially including L3a development. The
signaling of these nuclear hormone receptors could presumably be
altered by the presence of exogenous ligands. Indeed, the sole nuclear
hormone receptor with a characterized ligand in S. stercoralis,
Ss-DAF-12, regulates L3a development [15,22]. Recent work has
delineated the biosynthetic pathway for the steroid hormone
Δ7-dafachronic acid, which is the endogenous ligand for Ss-DAF-12, in
S. stercoralis and demonstrated that it can act synergistically with iver
mectin to control hyperinfection in the gerbil model [15].
Exogenous administration of Δ7-dafachronic acid inhibits the
development of S. stercoralis L3a in both the gerbil and NSG mouse
models of glucocorticoid-mediated hyperinfection [15,22]. Whether this
is the result of Δ7-dafachronic acid acting on the parasitic females
and/or the post-parasitic larvae remains unknown. Since dafachronic
acid decreases, rather than increases, the number of post-parasitic

larvae, it is unlikely that Δ7-dafachronic acid is acting solely on the
L3a. Three possible scenarios are that Δ7-dafachronic acid acts on 1) the
parasitic female to decrease larval output; 2) post-parasitic L1 to pro
mote development toward free-living larvae; or 3) post-parasitic L2 or
L3a in the lumen of the intestine and prematurely activates them,
thereby abrogating their ability to penetrate host tissue. The hypothesis
that Δ7-dafachronic acid promotes development of post-parasitic L1
into free-living larvae is supported by the fact that Δ7-dafachronic acid
inhibits the formation of L3i when post-parasitic larvae are cultured at
37 ◦ C [24], promotes development of a second free-living generation
[24,77], and activates iL3—evidenced by feeding [77], resulting in
changes in gene expression that are similar to host-adapted L3, which
are termed L3 + [78].
7. Future Directions
Given the advent of powerful immunoprofiling techniques including
multiparameter flow cytometry and single cell RNA-Seq, it will be quite
feasible to elucidate the immune cells in the NSG mouse (including tuft
cells and goblet cells) that are present prior to, and subsequently
reduced by, glucocorticoid administration. Likely candidates include the
myeloid subsets (neutrophils, eosinophils, and M2 macrophages) that
work in concert with extracellular trap formation and complement to
trap and kill larval stages. Curiously, even myeloid subsets (e.g.,
macrophage and dendritic cells) in NSG mice are known to bear ab
normalities. Given the migratory route taken by L3a during autoinfec
tion (i.e., small intestine, large intestine, lung), evaluation of local
immune infiltrates of different granulocyte and mononuclear cells
induced by parasites in mucosal tissues is critical for understanding the
key mechanisms that hold parasites in check. It is possible that following
glucocorticoid administration, these hematopoietic effector cells, in
combination with mucosal epithelial cells (i.e., tuft cells and goblet
cells), are rendered ineffective for larval killing/control. It is intriguing
to speculate that in addition to eliminating host mechanisms that limit
worm survival, glucocorticoids could also impact parasite biology in
ways that render worms resistant to killing. Although transcriptome
profiles for most S. stercoralis developmental stages have been
completed using RNA-Seq [62,76,78], the transcriptomic profiles of L3a
and parasitic females within a host undergoing hyperinfection are un
known. Having these transcriptomic profiles would almost certainly
bring insights into the potential mechanisms governing hyperinfection.
Comparative studies with S. ratti, in which glucocorticoid treatment
maintains parasite fecundity over the course of an infection but does not
result in hyperinfection [26,27], may also be informative in identifying
glucocorticoid-responsive genes that may drive autoinfection in
S. stercoralis. Recent advances in single worm RNA-Seq [79] should also
allow researchers to determine whether populations of parasitic females
and post-parasitic larvae have uniform or heterogeneous transcriptomic
profiles. Studies employing single worm RNA-Seq of parasites both preand post-glucocorticoid administration in an amenable rodent model
like the NSG mouse or Mongolian gerbil could reveal whether L3a are
generated by all or only a subpopulation of parasitic females and
whether glucocorticoids bias L1 development towards L3a relative to
iL3.
Once the putative glucocorticoid-sensitive regulatory factors in the
S. stercoralis transcriptome that control L3a development have been
identified, one would then have the capability to rigorously test their
biological role(s) by either selectively editing these genes using CRISPR/
Cas9 or over-expressing these genes using the piggyBac transposon sys
tem [80]. Advances in CRISPR/Cas9 mutagenesis methodologies have
allowed researchers to create targeted deletions in multiple S. stercoralis
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